BR112023022705A2 - Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares - Google Patents

Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Info

Publication number
BR112023022705A2
BR112023022705A2 BR112023022705A BR112023022705A BR112023022705A2 BR 112023022705 A2 BR112023022705 A2 BR 112023022705A2 BR 112023022705 A BR112023022705 A BR 112023022705A BR 112023022705 A BR112023022705 A BR 112023022705A BR 112023022705 A2 BR112023022705 A2 BR 112023022705A2
Authority
BR
Brazil
Prior art keywords
intravitrual
treatment
pharmaceutical compositions
drug delivery
delivery systems
Prior art date
Application number
BR112023022705A
Other languages
English (en)
Inventor
Dawn Glendenning Angela
Cheng-Wen Lin
Sevgi Gurkan
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Publication of BR112023022705A2 publication Critical patent/BR112023022705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente divulgação se relaciona com um implante ocular biodegradável, compreendendo um polímero biodegradável contendo um composto, tal como edonentan, ou um seu sal farmaceuticamente aceitável. são também divulgados métodos de tratamento de doenças oculares com o implante ocular biodegradável e seus métodos de preparação.
BR112023022705A 2021-04-30 2022-04-29 Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares BR112023022705A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182559P 2021-04-30 2021-04-30
US202163287737P 2021-12-09 2021-12-09
PCT/US2022/027048 WO2022232588A1 (en) 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
BR112023022705A2 true BR112023022705A2 (pt) 2024-01-16

Family

ID=83848732

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022705A BR112023022705A2 (pt) 2021-04-30 2022-04-29 Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares

Country Status (10)

Country Link
US (2) US11786510B2 (pt)
EP (1) EP4329753A1 (pt)
JP (1) JP2024515826A (pt)
KR (1) KR20240004643A (pt)
AU (1) AU2022264036A1 (pt)
BR (1) BR112023022705A2 (pt)
CA (1) CA3218251A1 (pt)
IL (1) IL307997A (pt)
MX (1) MX2023012723A (pt)
WO (1) WO2022232588A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005063A (es) 2019-10-30 2022-08-04 Perfuse Therapeutics Inc Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4282793A (en) 1992-04-10 1993-11-18 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
HUP0303005A3 (en) 2001-02-02 2005-05-30 Merck Patent Gmbh Pharmaceutical compositions comprising pyrazolo[4,3-d]pyrimidines or thienopyrimidines and endothelin receptor antagonists
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
WO2009026517A2 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
CA2759795C (en) 2009-04-30 2016-11-29 Midwestern University Method and composition for treating diabetic ketoacidosis
US20110082151A1 (en) 2009-06-12 2011-04-07 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
TW201204366A (en) 2010-04-12 2012-02-01 R Tech Ueno Ltd Ophthalmic composition for treating retinal disease
JP6511401B2 (ja) 2013-02-15 2019-05-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続型薬物送達インプラント
MY177958A (en) 2013-10-31 2020-09-28 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
BR112016014182A2 (pt) 2013-12-19 2017-08-08 Georgiou Tassos Composições de ácidos graxos ômega 3 para tratar doenças que envolvem danos ao sistema nervoso
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
JP2018522942A (ja) * 2015-05-29 2018-08-16 エッジ セラピューティクス インコーポレイテッド 視力障害を低減するための組成物及び方法
CN115337254A (zh) 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018236814A2 (en) 2017-06-19 2018-12-27 Gangadhara Ganapati NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF
WO2019018350A1 (en) * 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
CN113784727B (zh) 2019-03-05 2024-03-29 爱瑞制药公司 用于治疗眼部疾病或病症的药物组合物
MX2022005063A (es) 2019-10-30 2022-08-04 Perfuse Therapeutics Inc Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.
KR20220143685A (ko) 2020-02-06 2022-10-25 퍼퓨즈 세라퓨틱스, 인크. 안질환의 치료를 위한 조성물

Also Published As

Publication number Publication date
US20230105507A1 (en) 2023-04-06
WO2022232588A1 (en) 2022-11-03
CA3218251A1 (en) 2022-11-03
EP4329753A1 (en) 2024-03-06
JP2024515826A (ja) 2024-04-10
IL307997A (en) 2023-12-01
KR20240004643A (ko) 2024-01-11
MX2023012723A (es) 2024-02-08
US20230414577A1 (en) 2023-12-28
AU2022264036A1 (en) 2023-11-23
US11786510B2 (en) 2023-10-17

Similar Documents

Publication Publication Date Title
CA2909160C (en) Formulations of oxabicycloheptanes and oxabicycloheptenes
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
AR068816A1 (es) Composiciones de brimonidina mejorada para el tratamiento del eritema
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
van der Merwe et al. Endophthalmitis prophylaxis with intracameral cefuroxime in South Africa
MD3548091T2 (ro) Prepararea complexelor solide de ciclodextrină pentru livrarea ingredientelor farmaceutice active oftalmice
CN110139649A (zh) 用谷氨酰胺酶抑制剂的组合疗法
MX2023002902A (es) Inserto bioerosionable de administracion ocular de farmacos y metodo terapeutico.
BR112023022705A2 (pt) Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares
EA202191684A1 (ru) Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии
KR20190120197A (ko) 치료 및 신경보호 펩티드
RU2545798C1 (ru) Фармацевтическая композиция для оказания первой медицинской помощи при ожогах различной этиологии, площади и глубины в форме спрея, геля, аэрозоля
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
RU2416394C1 (ru) Фармацевтическая композиция в виде спрея для лечения раневых поверхностей
US10279046B2 (en) Eye drop composition for treating ocular inflammatory disease and preparation method therefor
US20200316075A1 (en) Ganciclovir compositions and related methods
Zhang et al. Preparation and evaluation of a novel biodegradable long-acting intravitreal implant containing ligustrazine for the treatment of proliferative vitreoretinopathy
RU2020124373A (ru) Профилактический агент и/или терапевтический агент для катаракты, медицинский состав для предотвращения и/или лечения катаракты, применение ppar-активатора для тех же целей и глазные капли
AR077458A1 (es) Composiciones de copolimero en bloque de oxido de etileno oxido de butileno
Thakur et al. Role of low dose mitomycin C in pterygium surgery
CN108272792B (zh) 一种抑制耐甲氧西林金黄色葡萄球菌生物被膜的组合物
RU2419417C1 (ru) Фармацевтическая композиция в виде раствора флуконазола, обладающая противогрибковым действием
WO2014204357A3 (ru) Лекарственное средство для лечения кератоконуса